|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1999-12-10
|
|
pubmed:abstractText |
Citicoline (cytidine-5'-diphosphocholine; CDP-choline) may reduce central nervous system ischemic injury by stabilizing cell membranes and reducing free radical generation. A previous dose-comparison trial in patients with acute stroke found that 500 mg of citicoline appeared to improve neurological outcome with minimal side effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0039-2499
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2592-7
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10582983-Aged,
pubmed-meshheading:10582983-Algorithms,
pubmed-meshheading:10582983-Cytidine Diphosphate Choline,
pubmed-meshheading:10582983-Double-Blind Method,
pubmed-meshheading:10582983-Female,
pubmed-meshheading:10582983-Humans,
pubmed-meshheading:10582983-Infarction, Middle Cerebral Artery,
pubmed-meshheading:10582983-Logistic Models,
pubmed-meshheading:10582983-Male,
pubmed-meshheading:10582983-Nootropic Agents,
pubmed-meshheading:10582983-Odds Ratio
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
A randomized efficacy trial of citicoline in patients with acute ischemic stroke.
|
|
pubmed:affiliation |
Oregon Stroke Center, Oregon Health Sciences University, Portland 97201, USA. Clarkw@ohsu.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
